Advertisement


Ralph R. Weichselbaum, MD, on Radiotherapy and Immunotherapy in Oligometastatic Disease

AACR Virtual Annual Meeting 2020 II

Advertisement

Ralph R. Weichselbaum, MD, of the University of Chicago Cancer Research Center, explores the question of whether radiotherapy is the principal curative treatment with immunotherapy or activates immunotherapy. He also discussed how to improve the interaction of these treatments, perhaps with vaccination, transfer of genetically engineered T cells, or checkpoint inhibitors (Session ED37).



Related Videos

Immunotherapy

Silvia Formenti, MD, on Testing Radiation and Immune Checkpoint Blockade in Different Tumor Settings

Silvia Formenti, MD, of Weill Cornell Medical College, discusses her continuing work, and the promising results emerging, in combining radiotherapy with immunotherapy to boost abscopal response rates. This combination therapy extends the use of radiotherapy to promote antitumor T-cell responses for both local and metastatic disease (Session ED37).

Issues in Oncology

Stacey A. Fedewa, PhD, on Cancers in Younger Populations: Current Trends

Stacey A. Fedewa, PhD, of the American Cancer Society, discusses the increasing incidence rates of colorectal, breast, kidney, thyroid, uterine corpus, and cervical disease in younger patients. Data show that colorectal cancer is increasing most rapidly, while breast cancer—the most common cancer among young women­­—is rising at a slower pace (Session ED35).

Lung Cancer

Ramaswamy Govindan, MD, on Differences Among Male and Female Patients With Lung Cancer

Ramaswamy Govindan, MD, of Washington University School of Medicine, discusses sex differences in lung cancer, including variations in treatment response, and the state of research in the field (Session ED20).

Gynecologic Cancers

Kala Visvanathan, MD, on Ovarian Cancer: Lowering Mortality With Lipophilic Statins

Kala Visvanathan, MD, of Johns Hopkins Bloomberg School of Public Health, discusses her analysis of data from more than 10,000 women with ovarian cancer. The results suggest that atorvastatin and simvastatin, lipophilic statin cholesterol-lowering drugs, reduced ovarian cancer death rates (Abstract 5782).

Lung Cancer
Immunotherapy

Nasser K. Altorki, MD, on Lung Cancer: Radiotherapy and Immune Checkpoint Blockade in the Neoadjuvant Setting

Nasser K. Altorki, MD, of Weill Cornell Medical College, discusses study findings that suggest neoadjuvant low-dose focal stereotactic body radiation plus immune checkpoint blockade (ICB) is safe and causes no surgical delays in early-stage lung cancer, and that major pathologic response rates are likely to be comparable to those with chemotherapy/ICB combinations (Session ED37).

Advertisement

Advertisement



Advertisement